Altasciences Performs Phase I Studies for FDA Approval of Vibegron
Altasciences Performs Phase I Studies for FDA Approval of Vibegron Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (ß3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020. " We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of pat...
Source: finanznachrichten.de